Skip to main content
. Author manuscript; available in PMC: 2021 Feb 15.
Published in final edited form as: Clin Cancer Res. 2020 May 12;26(16):4268–4279. doi: 10.1158/1078-0432.CCR-20-0056

Figure 1. Changes in tumor size and duration on the treatment.

Figure 1.

a) Changes in tumor size on the study treatment.

b) Duration in the study.

Abbreviations: S = platinum-sensitive recurrent ovarian cancer, R = platinum-resistant recurrent ovarian cancer, HRD = homologous recombination deficiency.